Hemostemix Announces that, Due to the COVID-19 Pandemic, the Annual and Special Meeting Will Only Be Held via Zoom and Shareholders are Requested to Follow the Meeting Instructions Mailed to the Shareholders of Record May 31, 2021
Hemostemix Announces the TSX Venture’s Preliminary Approval of the Closing of a $2,500,000 Convertible Debenture at $0.40 per Unit and Corporate Update May 29, 2021
RepliCel Launches Preparations for Second Skin Rejuvenation and Tendon Regeneration Clinical Studies May 19, 2021 Life Science
What healthcare stocks are heating up? – June 10, GCFF Healthcare Virtual Event May 17, 2021 Life Science, Technology
RepliCel Announces Appointment of Leading Dermatologist in Japan as Clinical Advisor May 17, 2021 Life Science, Technology
RepliCel Launches the Next Stage of a Research Project with the University of British Columbia to Build World-Class Hair Follicle Cell Data Map May 11, 2021 Life Science, Technology
RepliCel Announces Appointment of Leading Sports Medicine Expert as Orthopedics Clinical Advisor (Japan) May 3, 2021 Life Science, Technology
Hemostemix Provides a Clinical Trial Update and Announces the Release and Filing of 2020 Year-end Audited Financial Statements and Management Discussion and Analysis Apr 30, 2021 Life Science, Technology
Rethinking the approach to diagnose cancer | VolitionRx Limited Apr 30, 2021 Life Science, Technology
RepliCel Closes Second Tranche of Strategic Investment Commitment Apr 29, 2021 Life Science, Technology
Hemostemix Reprices and Amends the Terms of Its Unit Offering and Debenture Offering Apr 26, 2021 Life Science, Technology
Hemostemix Announces Completion of Phase II Clinical Trial Subject Follow Up and HMTXF Up-list Apr 23, 2021 Life Science, Technology
